Evidence map›Paper›PMID 38847519›Full record

ArticleCancer medicine2024

Explainable machine learning predicts survival of retroperitoneal liposarcoma: A study based on the SEER database and external validation in China.

Maoyu Wang, Zhizhou Li, Shuxiong Zeng, Ziwei Wang, Yidie Ying, Wei He, Zhensheng Zhang, Huiqing Wang, Chuanliang Xu

Abstract readValidation Study
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maoyu WangDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.ORCID 0000-0002-0022-187X
Zhizhou LiDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Shuxiong ZengDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Ziwei WangDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Yidie YingDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Wei HeDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Zhensheng ZhangDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Huiqing WangDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Chuanliang XuDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.

Funding

National Natural Science Foundation of China 81772720National Natural Science Foundation of China 81972391National Natural Science Foundation of China 82172871
6 · The paper itself

Abstract

objectiveWe have developed explainable machine learning models to predict the overall survival (OS) of retroperitoneal liposarcoma (RLPS) patients. This approach aims to enhance the explainability and transparency of our modeling results.

methodsWe collected clinicopathological information of RLPS patients from The Surveillance, Epidemiology, and End Results (SEER) database and allocated them into training and validation sets with a 7:3 ratio. Simultaneously, we obtained an external validation cohort from The First Affiliated Hospital of Naval Medical University (Shanghai, China). We performed LASSO regression and multivariate Cox proportional hazards analysis to identify relevant risk factors, which were then combined to develop six machine learning (ML) models: Cox proportional hazards model (Coxph), random survival forest (RSF), ranger, gradient boosting with component-wise linear models (GBM), decision trees, and boosting trees. The predictive performance of these ML models was evaluated using the concordance index (C-index), the integrated cumulative/dynamic area under the curve (AUC), and the integrated Brier score, as well as the Cox-Snell residual plot. We also used time-dependent variable importance, analysis of partial dependence survival plots, and the generation of aggregated survival SHapley Additive exPlanations (SurvSHAP) plots to provide a global explanation of the optimal model. Additionally, SurvSHAP (t) and survival local interpretable model-agnostic explanations (SurvLIME) plots were used to provide a local explanation of the optimal model.

resultsThe final ML models are consisted of six factors: patient's age, gender, marital status, surgical history, as well as tumor's histopathological classification, histological grade, and SEER stage. Our prognostic model exhibits significant discriminative ability, particularly with the ranger model performing optimally. In the training set, validation set, and external validation set, the AUC for 1, 3, and 5 year OS are all above 0.83, and the integrated Brier scores are consistently below 0.15. The explainability analysis of the ranger model also indicates that histological grade, histopathological classification, and age are the most influential factors in predicting OS.

conclusionsThe ranger ML prognostic model exhibits optimal performance and can be utilized to predict the OS of RLPS patients, offering valuable and crucial references for clinical physicians to make informed decisions in advance.

Indexed as

LiposarcomaMachine LearningRetroperitoneal NeoplasmsSEER ProgramAdultAgedChinaFemaleHumansMaleMiddle AgedPrognosisProportional Hazards ModelsRisk Factorsexplainable machine learningoverall survivalretroperitoneal liposarcomaSurvLIMESurvSHAP

Identifiers

PMID38847519
PMCPMC11157677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.